Please ensure Javascript is enabled for purposes of website accessibility

Will These Numbers from ViroPharma Be Good Enough for You?

By Seth Jayson - Updated Apr 10, 2017 at 1:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Checking expectations

ViroPharma (Nasdaq: VPHM) is expected to report Q1 earnings around April 26. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will wither -19.8% and EPS will wither -20.0%.

The average estimate for revenue is $109.0 million. On the bottom line, the average EPS estimate is $0.20.

Revenue details
Last quarter, ViroPharma logged revenue of $106.5 million. GAAP reported sales were 27% lower than the prior-year quarter's $145.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS were -$0.09 for Q4 versus $0.65 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 71.6%, much worse than the prior-year quarter. Operating margin was -4.2%, much worse than the prior-year quarter. Net margin was -5.3%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $463.1 million. The average EPS estimate is $0.82.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,200 members out of 1,239 rating the stock outperform, and 39 members rating it underperform. Among 314 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 308 give ViroPharma a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $32.81.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.